We are live on ! Find out more

Recursion Pharmaceuticals

RXRX

Market cap $1.72B

3.20 USD

+0.04

1.27%

At close Updated Sep 11, 4:00 PM EDT

Pre-market

After hours

3.20

0.00

0%

1 day

1.27%

5 days

-6.43%

1 month

-4.48%

3 months

1.59%

6 months

-7.25%

Year to date

-23.81%

1 year

-34.02%

5 years

-87.73%

10 years

-89.78%

About: Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.

Employees: 600

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 30%

Neutral 50%

Negative 20%

Zacks Investment Research

Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today

Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $3.16, signifying a -1.71% move from its prior day's close.

Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today

The Motley Fool

2 Beaten-Down Stocks to Avoid Right Now

Teladoc's business isn't making much progress, despite expanding insurance coverage within one of its most important segments. Recursion Pharmaceuticals claims that its approach to drug development is superior, but so far, it has yet to prove that claim.

2 Beaten-Down Stocks to Avoid Right Now

Zacks Investment Research

Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report?

Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock?

Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report?

Zacks Investment Research

Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook?

Recursion Pharmaceuticals is expanding its clinical pipeline across oncology and rare diseases, with REC-4881 and multiple programs offering potential growth catalysts.

Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook?

Zacks Investment Research

4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma

RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.

4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma

Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updates

Recursion Pharmaceuticals NASDAQ: RXRX is using artificial intelligence to generate and analyze biological data in an effort to improve drug discovery, advance internal therapeutic programs and support collaborations with larger pharmaceutical companies, CFO and President of Recursion U.K. Ben Taylor said during a BofA Global Research virtual conference.

Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updates

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America SMID Cap Virtual Conference Transcript

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America SMID Cap Virtual Conference Transcript

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America SMID Cap Virtual Conference Transcript

Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech News

Recursion Pharmaceuticals, Inc. remains a Hold as competitive advances and slow revenue growth challenge its AI-driven drug discovery ambitions. RXRX's partnerships, notably with Genentech/Roche and Sanofi, have delivered $500M+ in milestone payments, but further commercial validation is pending. The internal pipeline, led by REC-4881 for FAP, potentially lags competitors (more data is required) and is unlikely to generate significant revenue before 2030.

Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech News

Zacks Investment Research

RXRX Q2 Earnings Miss Estimates, Revenues Fall Y/Y, Stock Down

Recursion misses Q2 earnings and revenue estimates as collaboration revenues fall year over year, sending shares lower while pipeline and partnership programs advanced.

RXRX Q2 Earnings Miss Estimates, Revenues Fall Y/Y, Stock Down

Recursion Pharmaceuticals Q2 Earnings Call Highlights

Recursion Pharmaceuticals NASDAQ: RXRX outlined progress across its clinical pipeline, drug-discovery partnerships and AI-enabled research platform, while lowering its 2026 cash operating expense guidance to $375 million and reaffirming expectations for an operating runway through early 2028.

Recursion Pharmaceuticals Q2 Earnings Call Highlights

See News Rankings

Price charts implemented using Lightweight Charts™